SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SCYNEXIS (Nasdaq: SCYX) announced inducement equity awards approved April 30, 2026 for a newly hired Vice President.

Rhea-AI Summary

SCYNEXIS (Nasdaq: SCYX) announced inducement equity awards approved April 30, 2026 for a newly hired Vice President. The grants include stock options for 125,000 shares at an exercise price of $0.93 and 20,000 RSUs.

Options vest over four years starting April 13, 2026; RSUs vest in three equal annual installments beginning June 15, 2026. Awards were granted under the company’s 2015 Inducement Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Argus May 7 session

-2.51% close to close Open Argus

Details

News Market Reaction – SCYX

On May 7, the first trading day after this news, SCYX closed 2.51% below the previous close.

Data tracked by StockTitan Argus for the May 7 session.

Key Figures

Current share price: $0.9819 Inducement option grant: 125,000 options Option exercise price: $0.93 per share +5 more

Current share price

$0.9819

Pre-news market context

Inducement option grant

125,000 options

New VP inducement award

Option exercise price

$0.93 per share

Closing price on April 30, 2026

Inducement RSUs

20,000 RSUs

New VP inducement award

Vest period options

4 years

25% at one year, then monthly over 36 months

Vest period RSUs

3 years

Three equal annual installments

Registered resale shares

87,000,000 shares

S-3 shelf for private placement purchasers

Shares outstanding

79,442,633 shares

As of April 1, 2026 (S-3 filing)

Historical Context

5 past events · Latest: Mar 31

5 events

1. Mar 31

   Asset sale/licensing

   24h Move

   +16.1%

   Sale of PXL770 (SCY-770) with up to $196M in total consideration.

2. Mar 31

   Financing deal

   24h Move

   +16.1%

   $40M private placement plus warrant upside extending cash runway into mid-2029.

3. Mar 31

   Asset acquisition

   24h Move

   +16.1%

   Completion of transformative acquisition of SCY-770 for ADPKD development.

4. Mar 04

   Earnings update

   24h Move

   +2.3%

   Full-year 2025 results with higher revenue, GSK payment, and >2-year runway.

5. Feb 26

   Clinical trial start

   24h Move

   -0.7%

   First participants dosed in Phase 1 IV SCY-247 SAD/MAD trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock units, vesting, autosomal dominant polycystic kidney disease

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"approved inducement equity awards ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock units financial

"and restricted stock units (“RSUs”) covering 20,000 shares of the Company’s common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"the shares underlying the option vesting on the on-year anniversary of the vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

autosomal dominant polycystic kidney disease medical

"SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced"

A hereditary kidney disorder in which fluid-filled sacs (cysts) form and grow on the kidneys, often caused when a single parent passes down a faulty gene. Over time the cysts can reduce kidney function and lead to serious health care needs, making it important to investors because it drives demand for diagnostic tests, drugs, medical devices and long-term care, and influences clinical trial activity and regulatory milestones.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company’s Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee’s acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The awards were granted pursuant to SCYNEXIS’ 2015 Inducement Award Plan, as amended, which was adopted by the Company’s Board of Directors in March 2015 under Rule 5635(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

The inducement awards consist of stock options to purchase 125,000 shares of the Company’s common stock at a per share exercise price of $0.93, the closing price per share of the Company’s common stock as reported by Nasdaq on April 30, 2026, and restricted stock units (“RSUs”) covering 20,000 shares of the Company’s common stock. The employee’s stock options have a vesting commencement date of April 13, 2026, vest over a four-year period, with 25% of the shares underlying the option vesting on the on-year anniversary of the vesting commencement date, and the remaining shares vest in equal monthly installments thereafter over 36 months, subject to the employee’s continued service with the Company. The employee’s RSUs have a vesting commencement date of June 15, 2026, and vest in three equal annual installments over a three-year period, subject to the employee’s continued service through each applicable vesting date.

About SCYNEXIS, Inc.

SCYNEXIS, Inc. (NASDAQ: SCYX) is dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME^® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com.

CONTACT:
Investor Relations
LifeSci Advisors

John Fraunces
T: 917-355-2395
jfraunces@lifesciadvisors.com

Source: Scynexis

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did SCYNEXIS (SCYX) grant on April 30, 2026?

SCYNEXIS granted stock options for 125,000 shares and 20,000 RSUs as inducement awards. According to the company, the options carry a $0.93 exercise price, the Nasdaq closing price on April 30, 2026, and were approved under Nasdaq Rule 5635(c)(4).

What is the vesting schedule for the SCYNEXIS (SCYX) stock options awarded to the new VP?

The stock options vest over a four-year period with 25% vesting on the one-year anniversary. According to the company, the vesting commencement date is April 13, 2026, and remaining shares vest monthly over the following 36 months, subject to continued service.

When do the SCYNEXIS (SCYX) RSUs granted to the new VP begin vesting and over what period?

The RSUs have a vesting commencement date of June 15, 2026 and vest in three equal annual installments. According to the company, vesting is subject to the employee’s continued service through each applicable vesting date.

Under what plan and Nasdaq rule were the SCYNEXIS (SCYX) inducement awards granted?

The awards were granted under the company’s 2015 Inducement Award Plan pursuant to Nasdaq Listing Rule 5635(c)(4). According to the company, the inducement grants were approved as material inducements to the new hire’s acceptance of employment.

What exercise price was set for the SCYNEXIS (SCYX) options and how was it determined?

The exercise price for the options was set at $0.93 per share, equal to the Nasdaq closing price on April 30, 2026. According to the company, that closing price was used as the per-share exercise price for the inducement grant.